Simple blood test may spot postpartum depression risk during pregnancy

NCT ID NCT06831968

Recruiting now Diagnosis Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new blood test called the Enlighten Device to see if it can predict which pregnant women will develop postpartum depression (PPD). Researchers will collect blood from 500 pregnant women in their third trimester and then follow them for 6 months after birth to track depression symptoms. The goal is to see if the test can accurately identify women at high risk, so they can get early support. The test is still investigational and not yet approved by the FDA.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enlighten Device (blood-based epigenetic biomarker test)
What this could lead to: If successful, this blood test could help identify pregnant women at risk for postpartum depression, allowing for early monitoring or support.
What could go wrong: This is an early-stage observational study, not yet FDA-approved. The test may not accurately predict depression, and results are not shared with participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION (PPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postpartum depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTPARTUM DEPRESSION (PPD) PREGNANCY

Contacts and locations

Locations

Inova Health System
RECRUITING

Falls Church, Virginia, 22042, United States
University of Virginia
RECRUITING

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.